Ypsomed AG

Ypsomed’s platform portfolio offers advanced self-injection devices, including reusable and prefilled pens, autoinjectors, wearable injectors, and digital health solutions. Each platform is engineered in Switzerland for fast, efficient customisation, significantly reducing time to market and minimising dev...

YpsoMate 5.5 autoinjector is an automated injection device for 5.5mL pre-filled glass syringes suitable for all patient groups. The device is triggered by push-on-skin activation which is convenient, ergonomic and preferred by patients.
• Taking handheld self-injection beyond volumes of 2.0 m...

Ypsomed provides pharmaceutical companies with fully integrated digital solutions. Our platform combines connected injection devices with comprehensive digital patient tools. Our aim is to facilitate research and development, shorten market access timelines and improve commercial success of subcutaneo...

Ypsomed’s broad range of injection pens covers reusable and disposable injection systems for various therapy areas where liquid stable drugs are provided in cartridges for frequent injections.

Ypsomed’s pen injector platform portfolio consists:
• ServoPen – the automatic reusable pen:&nb...

Ypsomed’s autoinjector systems are automated disposable injection devices for 1ml and 2.25ml filled glass or polymer syringes suitable for all patient groups. The Ypsomed autoinjector family is typically used for the growing range of infrequently injected antibody-based drugs.

Ypsomed’s auto...

Patch injectors solve the need for the infrequent injection of biologics in the 2 – 10 ml volume range. Ypsomed offers a pre-filled patch injector platform as a new self-injection device class to complement the established and growing markets for pens and autoinjectors.
 
Ypsomed’s device of...

First introduced during the 2023 fall conference season, Ypsomed’s Reusable Autoinjector is a patient-centric device platform solution for subcutaneous drug delivery. It consists of a reusable drive unit with an electromechanical drive mechanism and a disposable cassette with needle stick protection.
q...

We proudly launch our proven YpsoMate® platform products equipped with the BD Neopak™ XtraFlow™ PFS with 8 mm needle and thin wall cannula. This new cutting-edge solution meets high-dose drug formulation demands by efficiently handling high viscosities and volumes. It highlights the strength of our Yps...

Alliance to Zero aims to facilitate the transition of the pharma sector to reach net zero emissions target

Speed up time-to-market with customised platform products

Combine SmartPilot with YpsoMate and begin capturing accurate, unbiased injection data while enabling intuitive, step-by-step user guidance. Transforming the proven YpsoMate autoinjector into a fully connected digital health solution facilitates your big data strategy.

YpsoDose is the ready-to-use patch injector with minimum use steps to administer drug volumes up to 10 mL. With its intuitive use concept and ingenious technical solutions it ensures comfortable and safe injections for all conditions and environments while adapting to your formulation needs. It’s more than a device – it’s a reliable partner for patients, caregivers, and HCPs.

Count on performance: Ypsomed is shaping the world of subcutaneous self-injection. This short video shows what that means in numbers.

UnoPen and YpsoPen are two of Ypsomed’s pen platforms developed and customized on behalf of various pharma customers for patients dependent on peptide hormones, in particular insulin but also GLP-1, hGH, FSH and PTH. Demand for these devices has increased over the last years and has now exceeded the total of 100 million UnoPen and 10 million YpsoPen delivered units. This achievement was celebrated with all colleagues involved at our Swiss facilities in Burgdorf and Solothurn.

Ypsomed's NetZero Program is a greenhouse gas emissions reduction roadmap aiming for net zero emissions  across the entire value chain by 2040. Through NetZero products, CO2 footprint is minimised by using renewable materials, optimising packaging, and establishing sustainable operating procedures. The program includes a mass balance approach and offsetting of remaining carbon emissions. All three manufacturing sites are certified by ISCC, and the first YpsoMate NetZero product was delivered in autumn 2023.

Methotrexate is frequently used in the treatment of certain autoimmune conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, and juvenile idiopathic arthritis. Subcutaneous application offers significant advantages over oral administration. medac has chosen our buttonless autoinjector as the successor model to their previous MTX PEN, enhancing the ease of injection for patients. Comprehensive market research was conducted to understand the needs of users and identify the most relevant features for the new device.

In line with our commitment to sustainability, Ypsomed has been making significant strides in promoting renewable energy. Since 2021, we have sourced 100 % of our electricity from renewable sources. Our efforts have now extended to generating renewable electricity on-site through photovoltaic systems. This year, we proudly commissioned a new solar system at our site in Schwerin, Germany.

Ypsomed announces that its production facility in Schwerin, Germany, has now begun manufacturing the flagship UnoPen, marking a key milestone in enhancing production capacity and supply chain efficiency. This development strengthens our ability to deliver high-quality solutions to our current and future pharmaceutical partners worldwide.

UnoPen and YpsoPen are two of Ypsomed’s pen platforms developed and customized on behalf of various pharma customers for patients dependent on peptide hormones, in particular insulin but also GLP-1, hGH, FSH and PTH. Demand for these devices has increased over the last years and has now exceeded the total of 100 million UnoPen and 10 million YpsoPen delivered units. This achievement was celebrated with all colleagues involved at our Swiss facilities in Burgdorf and Solothurn.

Filter our proven self-injection devices according to your needs and discover the match for your drug product.

Burgdorf, 23.10.2024, 1:00 p.m. – Ypsomed (SIX: YPSN) announced a strategic collaboration with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, to advance self-injection solutions for high-viscosity biologic drugs. In a joint project, Ypsomed and BD have streamlined integration of the BD Neopak XtraFlow Glass Prefillable Syringe with Ypsomed’s YpsoMate 2.25 autoinjector platform, addressing current limitations by enabling the delivery of higher viscosity (>15cP) biologic drugs in an autoinjector format.

The number of people with chronic conditions is increasing worldwide. In this context, the demand forYpsomed’s autoinjectors and pens is growing rapidly, as they enable simple and safe self-administration ofliquid medication. In conversation with Susanne Köhler, Head of Public Relations, Ulrike Bauer, Chief BusinessOfficer Delivery Systems at Ypsomed, talks about current trends and how the company’s commitment to strongpartnerships, scalable business models, and strategic market positioning makes Ypsomed an ideal partner formeeting the growing demand and driving sustainable innovation.

Burgdorf, 17.10.2024, 7 a.m. – Today Ypsomed celebrates the opening of a new production hall at its German site in Schwerin. The expansion will enable the company to increase its production capacity to meet the growing global demand for high-quality medical technology products. CEO of Ypsomed, Simon Michel, also announced a further expansion of the plant in the coming years.

Motivate. Contribute. Inspire.

First introduced during the 2023 fall conference season,Ypsomed’s Reusable Autoinjector is a patient-centricdevice platform solution for subcutaneous drug delivery.It consists of a reusable drive unit with an electromechanicaldrive mechanism and a disposable cassettewith needle stick protection.

CliniPilot integrates with YpsoMate® 1.0 and 2.25 autoinjectors, transforming them into powerful digital tools forclinical trials. It fits seamlessly into existing trial workflows, allowing adherence tracking and replacing manualdiaries with real-time, objective and reliable data to remove human errors and documentation burden. No regulatoryapproval is required, allowing for immediate application in clinical trials, and its compatibility with standardEDC systems ensures easy integration into existing trial setups.

The YpsoMate® 2.25 and YpsoMate® 2.25 Pro configurationwith an 8 mm needle enhances the trusted YpsoMate®platform by providing greater versatility and improved patientcomfort. It retains the familiar YpsoMate® ergonomic designwith push-on-skin activation, reducing development andregulatory risks while ensuring reliable performance. By offeringreduced injection force and time, it accommodates a widerange of drug formulations for various therapy needs.

FixPen is the easy-to-use pen for all multidose therapies requiring the injection of a fixed dose. In addition to a simple pull-push handling principle to inject the drug, FixPen combines various features to simplify handling and maximise patient convenience.

The YpsoPen is an intuitive variable dose insulin pen providing a familiar handling experience and high level of patient acceptance.

YpsoMate 5.5 large volume autoinjector is an automated injection device for 5.5 mL pre-filled glass syringes suitable for all patient groups. The device is triggered by push-on-skin activation which is convenient, ergonomic and preferred by patients. Fully customisable.

YpsoMate 2.25 and YpsoMate 2.25 Pro autoinjectors are automated injection devices for 2.25 mL pre-filled glass or polymer syringes suitable for all patient groups. They can be configured with either an 8 mm or a ½” needle. The device is triggered by push-on-skin activation which is convenient, ergonomic, and preferred by patients. The YpsoMate 2.25 Pro is suitable for a large range of viscosities.

The YpsoMate autoinjector is an automated injection device for 1 mL long pre-filled glass or polymer syringes suitable for all patient groups. The device is triggered by push-on-skin activation which is convenient, ergonomic and preferred by patients.The design can be customised for individual dosing requirements.

The UnoPen is an intuitive variable dose pen for insulin and other multidose therapies providing a familiar handling experience and high level of patient acceptance.